An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema
This phase 3b study will evaluate long-term safety and efficacy of CSL312 (also known as garadacimab) when administered subcutaneously (SC)
Inclusion Criteria:
Exclusion Criteria:
Brno, 65691, Czechia
Mainz, 55131, Germany
Budapest, 1088, Hungary
Tokyo, Midoricho, Tachikawa-shi 190-0014, Japan
Miyakojima-ku, Osaka-shi 534-0021, Japan